Gene therapy in ocular diseases

Indian Journal of Ophthalmology

Volumn 50, Issue 3, 2002, Pages 173-181

  Singh, Vijay K ^a,b   Tripathi, Parul ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b ARMED FORCES RADIOBIOLOGY RESEARCH INSTITUTE   (United States)

Author keywords

Gene therapy; Ocular diseases

Indexed keywords

ANIMAL; ANIMAL MODEL; CLINICAL TRIAL; EYE DISEASE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; HUMAN; METHODOLOGY; REVIEW;

ANIMALS; CLINICAL TRIALS; EYE DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MODELS, ANIMAL;

EID: 0036716589     PISSN: 03014738     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Mountain A. Gene therapy: The first decade. Trends Biotechnol 2000;18:120-8.
2. Fibison WJ. Gene therapy. Nurs Clin North Am 2000;35:757-64.
3. Tolstoshev P. Gene therapy, concepts, current trials and future directions. Ann Rev Pharmacol Toxicol 1993;32:573-96.
4. Culver KW. Gene Therapy- A primer for physicians. 2nd ed. New York: Mary Ann Liebert, Inc., 1996.
5. da Cruz L, Rakoczy P, Constable I. Ocular gene therapy: The basic science and current status of research. Aust N Z J Ophthalmol 1997;25:97-104.
6. Kremen J, Pohlreich P, Stribrna J. Vectors used in gene therapy. Sb Lek 1998;99:341-7.
7. Eck SL. The prospects for gene therapy. Hosp Pract 1999;15:67-75.
8. Nussenblatt RB, Csaky K. Perspective on gene therapy in the treatment of ocular inflammation. Eye 1997;11:217-21.
9. Reichel MB, Hudde T, Ali RR, Weidemann P. Gene transfer in ophthalmology. Ophthalmologe 1999;96:570-77.
10. Murata T, Kimura H, Sakamoto T, Osusky R, Spee C, Stout TJ, et al. Ocular gene therapy: Experimental studies and clinical possibilities. Ophthalmic Res 1997;29:242-51.
11. Ailles LE, Naldini L. HIV-1-derived lentiviral vectors. Curr Top Microbiol Immunol 2002;261:31-52.
12. Follenzi A, Naldini L. Generation of HIV-1 derived letiviral vectors. Methods Enzymol 2002;346:454-65.
13. Naldini L, Verma IM. Lentiviral vectors. Adv Virus Res 2000;55:599-609.
14. Vigna E, Naldini L. Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000:2:308-16.
15. Mashhour B, Couton D, Perricaudet M, Briand P. In vivo adenovirus mediated gene transfer into the ocular tissues. Gene Therapy 1994;1:122-26.
16. Tsai ML, Chen SL, Chou PI, Wen LY, Tsai RJ, Tsao YP. Inducible adeno-associated virus vector-delivered transgene expression in corneal endothelium. Invest Ophthalmol Vis Sci 2002;43:751-57.
17. Csaky K and Nussenblatt RB. Gene therapy in the treatment of ocular inflammation. Springer Sem Immunopathol 1999;21:191-7.
18. Trono D. Lentiviral vectors: Turning a deadly foe into a therapeutic agent. Gene Ther 2000;7:20-23.
19. Treco DA, Selden RF. Non viral gene therapy. Mol Med Today 1995;1:314-21.
20. Nishikawa M, Huang L. Nonviral vectors in the new millennium: Delivery barriers in gene transfer. Hum Gene Ther 2001;12:861-70.
21. Bennett J, Maguire AM. Gene therapy for ocular disease. Mol Ther 2000;1:501-5.
22. Hauswirth WW, Beaufrere L. Ocular gene therapy: Quo Vadis? Invest Ophthalmol Vis Sci 2000;41:2821-26.
23. Dejneka NS, Bennett J. Gene therapy and retinitis pigmentosa: Advances and future challenges. Bioessays 2001;23:662-68.
24. Bennett J. Gene therapy for retinitis pigmentosa. Current Opin in Mol Ther 2000;2:420-25.
25. Ikuno Y and Kazlauskas A. Recent progress in gene therapy for eye diseases. Gene Ther Mol Biol 1999;4:203-8.
26. Ali RR, Sarra GM, Stephens C, Alwis MD, Bainbridge JW, Munro PM, et al. Restoration of photoreceptor ultrastructure and function in retinal degeneration slows in mice by gene therapy. Nat Genet 2000;25:306-10.
27. Stout T. Gene therapy in ocular disease. Ophthalmology 1995;102:1415-16.
28. Hauswirth WW, Lewin AS. Ribozyme uses in retinal gene therapy. Prog Retin Eye Res 2000;19:689-10.
29. Hauswirth WW, LaVail MM, Flannery JG, Lewin AS. Ribozyme gene therapy for autosomal dominant retinal disease. Clin Chem Lab Med 2000;38:147-53.
30. Lewin AS, Drenser KA, Hauswirth WW, Nishikawa S, Yasumura D, Flannery JG, et al. Ribozyme rescue of photoreceptor cell in a transgenic rat model of autosomal dominant retinits pigmentosa. Nat Med 1998;4:967-71.
31. LaVail MM, Yasumura D, Matthes MT, Drenser KA, Flannery JG, Lewin AS, et al. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci USA 2000;97:11488-93.
32. McGee Sanftner LH, Rendahl KG, Quiroz D, Coyne M, Cadner M, Mannery WC, et al. Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. Mol Ther 2001;3:688-96.
33. Green ES, Rendahl KG, Zhou S, Ladner M, Coyne M, Srivastava R, et al. Two animal models of retinal degeneration are rescued by recombinant adenoassociated virus mediated production of FGF-2 and FGF-18. Mol Ther 2001;3:507-15.
34. Lau D, McGee LH, Zhou S, Rendahl KG, Manning WC, Escobedo JA, et al. Retinal degeneration is slowed in transgenic rats by AAV- mediated delivery of FGF-2. Invest Ophthalmol Vis Sci 2000;41:3622-33.
35. Liang FQ, Aleman TS, Dejneka NS, Dudus L, Fisher KJ, Maguire AM, et al. Long-term protection of retinal structure but not function using RAAV.CNTF in animal models of retinitis pigmentosa. Mol Ther 2001;4:461-72.
36. Ali RR, Reichel MB, Thrasher AJ, Levinsky RJ, Kinnon C, Kanuga N, et al. Gene transfer in to the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 1996;5:591-94.
37. Chatterjee PR, Dutta H, Sarkar K. Prospects of gene therapy for ocular diseases. J Indian Med Assoc 2000;98:746-47.
38. Hotta Y, Inana G. Expression of human ornithine aminotransferase (OAT) in OAT- deficient Chinese hamster ovary cells and fibroblasts of gyrate atrophy patient. Jpn J Ophthalmol 1992;36:28-32.
39. Lacorazza HD, Jendoubi M. Correction of ornithine-delta-aminotransferase deficiency in a Chinese hamster ovary cell line mediated by retrovirus gene transfer. Gene Ther 1995;2:22-28.
40. Sullivan DM, Jensen TG, Taichman LB, Csaky KG. Ornithine-delta- aminotransferase expression and ornithine metabolism in cultured epidermal keratinocytes: toward metabolic sink therapy for gyrate atrophy. Gene Ther 1997;4:1036-44.
41. Jensen TG, Sullivan DM, Morgan RA, Taichman LB, Nussenblatt RB, Blaese RM, et al. Retrovirus-mediated gene transfer of ornithine-delta-aminotransferase into keratinocytes from gyrate atrophy patients. Hum Gene Ther 1997;8:2125-32.
42. Wong CA, Jia W, Matsubara JA. Experimental gene therapy for an in vitro model of proliferative vitreoretinopathy. Can J Ophthalmol 1999;34:379-84.
43. Kimura H, Sakamoto T, Cardillo JA, Spee C, Hinton DR, Gordon EM, et al. Retrovirus mediated suicide gene transduction in the vitreous cavity of the eye: feasibility in prevention of proliferative vitreoretinopathy. Hum Gene Ther 1996;7:799-808.
44. Schubert CA, Kimura H, Spee C, Hinton DR, Gordon EM, Anderson WF, et al. Retrovirus-mediated transfer of the suicide gene into retinal pigment epithelial cells in vitro. Curr Eye Res 1997;16:656-62.
45. Sakamoto T, Kimura H, Scuric Z, Spee C, Gordon EM, Hinton DR, et al. Inhibition of experimental proliferative vitreoretinopathy by retroviral vector mediated transfer of suicide gene. Can proliferative vitreoretinopathy be a target of gene therapy? Ophthalmology 1995;102:1417-24.
46. Singh VK, Biswas S, Rai G, Agarwal SS. Immunomodulation in human and experimental uveitis: Recent advances. Indian J Ophthalmol 1999;47:65-77.
47. Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from an experimental autoimmune uveitis. J Clin Invest 2000;106:245-48.
48. Pleyer U, Dannowski H, Reszka R, Volk HD, Hartman C, Ritter T. Gene therapy in Ophthalmology. Review of options and trends in corneal diseases. Kliri Monatsbl Augenheilkd 2001;218:140-47.
49. Verma L, Das T, Binder S, Heriot WJ, Kirchhof B, Venkatesh P, et al. New approaches in the management of choroidal neovascular membrane in age-related macular degeneration. Indian J Ophthalmol 2000;48:263-78.
50. Stechschulte SU, Joussen AM, von Recum HA, Poulaki V, Moromizato Y, Yuan J, et al. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci 2001;42:1975-79.
51. Hangai M, Kaneda Y, Tanihara H, Honda Y. In vivo gene transfer into the retina mediated by a novel liposome system. Invest Ophthalmol Vis Sci 1996;37:2678-85.
52. Otsuji T, Ogata N, Takahashi K, Matsushima M, Uyama M, Kaneda Y, et al. In vivo gene transfer into the choroidal neovascularization by the HVJ liposome method. Graefes Arch Clin Exp Ophthalmol 2000;238:191-99.
53. Hurwitz MY, Marcus KT, Chevez-Barrios P, Louie K, Aguilar-Cordova E, Hurwitz RL. Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther 1999;10:441-48.
54. Hayashi N, Ido E, Ohtsuki Y, Ueno H. An experimental application of gene therapy for human retinoblastoma. Invest Ophthalmol Vis Sci 1999;40:265-72.
55. Acland GM, Aguirre GD, Ray J, Zhang Q, Aleman TS, Cideciyan AV, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001;28:92-95.
56. Bennet J, Tanabe T, Sun D, Zeng Y, Kjeldbye H, Gourar P, et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med 1996;2:649-54.
57. Verma IM, Somia N. Gene therapy-promises, problems and prospects. Nature 1997;389:239-42.
58. Zack DJ. Ocular gene therapy. From fantasy to foreseeable reality. Arch Ophthalmol 1993;111:1477-79.
59. Wright FA. Gene therapy for the eye. British J Ophthalmol 1997;81:620-23.
60. Van Tendeloo VF, Van Broeckhoven C, Berneman ZM. Gene therapy: Principles and applications to hematopoietic cells. Leukemia 2001;15:523-44.
61. Boyce N. Trial halted after gene shows up in semen. Nature 2001;414:677.
62. Pietrzyk JJ. Gene therapy-hopes and fears. Folia Med Cracov 1998;39:131-38.
63. Zelenin AV. Gene therapy: Ethical aspects and problems of genetic safety. Genetika 1999;35:1605-12.
64. Okada AA, Forrester JV. Ocular inflammatory disease in the new millennium. Arch Ophthalmol 2000;118:116-19.
65. Karpati G, Lochmuller H. The scope of gene therapy in humans: Scientific safety and ethical consideration. Neuromuscul Disord 1997;7:273-76.